Denali Therapeutics Statistics
Share Statistics
Denali Therapeutics has 143.92M shares outstanding. The number of shares has increased by 3.42% in one year.
| Shares Outstanding | 143.92M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.53% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 124.59M |
| Failed to Deliver (FTD) Shares | 395 |
| FTD / Avg. Volume | 0.04% |
Short Selling Information
The latest short interest is 7.46M, so 5.19% of the outstanding shares have been sold short.
| Short Interest | 7.46M |
| Short % of Shares Out | 5.19% |
| Short % of Float | 5.99% |
| Short Ratio (days to cover) | 8.62 |
Valuation Ratios
The PE ratio is -20.3 and the forward PE ratio is -10.87.
| PE Ratio | -20.3 |
| Forward PE | -10.87 |
| PS Ratio | 8.92 |
| Forward PS | 14.3 |
| PB Ratio | 2.86 |
| P/FCF Ratio | -7.95 |
| PEG Ratio | n/a |
Enterprise Valuation
Denali Therapeutics Inc. has an Enterprise Value (EV) of 2.87B.
| EV / Earnings | -19.78 |
| EV / Sales | 8.69 |
| EV / EBITDA | -15.96 |
| EV / EBIT | -14.61 |
| EV / FCF | -7.75 |
Financial Position
The company has a current ratio of 13.65, with a Debt / Equity ratio of 0.
| Current Ratio | 13.65 |
| Quick Ratio | 13.65 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.14% and return on capital (ROIC) is -18.16%.
| Return on Equity (ROE) | -0.14% |
| Return on Assets (ROA) | -0.13% |
| Return on Capital (ROIC) | -18.16% |
| Revenue Per Employee | 847.52K |
| Profits Per Employee | -372.37K |
| Employee Count | 390 |
| Asset Turnover | 0.29 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 30.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 2.12% in the last 52 weeks. The beta is 1.39, so Denali Therapeutics 's price volatility has been higher than the market average.
| Beta | 1.39 |
| 52-Week Price Change | 2.12% |
| 50-Day Moving Average | 24.05 |
| 200-Day Moving Average | 23.08 |
| Relative Strength Index (RSI) | 33.72 |
| Average Volume (20 Days) | 880.29K |
Income Statement
In the last 12 months, Denali Therapeutics had revenue of 330.53M and earned -145.22M in profits. Earnings per share was -1.06.
| Revenue | 330.53M |
| Gross Profit | 313.81M |
| Operating Income | -196.70M |
| Net Income | -145.22M |
| EBITDA | -179.97M |
| EBIT | -196.70M |
| Earnings Per Share (EPS) | -1.06 |
Balance Sheet
The company has 127.11M in cash and 52.24M in debt, giving a net cash position of 74.86M.
| Cash & Cash Equivalents | 127.11M |
| Total Debt | 52.24M |
| Net Cash | 74.86M |
| Retained Earnings | -1.12B |
| Total Assets | 1.45B |
| Working Capital | 781.75M |
Cash Flow
In the last 12 months, operating cash flow was -357.99M and capital expenditures -12.94M, giving a free cash flow of -370.93M.
| Operating Cash Flow | -357.99M |
| Capital Expenditures | -12.94M |
| Free Cash Flow | -370.93M |
| FCF Per Share | -2.7 |
Margins
Gross margin is 94.94%, with operating and profit margins of -59.51% and -43.94%.
| Gross Margin | 94.94% |
| Operating Margin | -59.51% |
| Pretax Margin | -43.93% |
| Profit Margin | -43.94% |
| EBITDA Margin | -54.45% |
| EBIT Margin | -59.51% |
| FCF Margin | -112.22% |
Dividends & Yields
DNLI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -5.65% |
| FCF Yield | -13.74% |
Analyst Forecast
The average price target for DNLI is $32, which is 70.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $32 |
| Price Target Difference | 70.6% |
| Analyst Consensus | Buy |
| Analyst Count | 13 |
Scores
| Altman Z-Score | 10.74 |
| Piotroski F-Score | 2 |